Maria N Chitasombat1, Dimitrios P Kontoyiannis. 1. aDivision of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand bFrances King Black Endowed Professor at Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: Mucormycosis is an opportunistic mold infection whose management is difficult, as there is a paucity of evidence-based data. We summarize the latest advances in diagnosis and management of mucormycosis in transplant recipients. RECENT FINDINGS: There is promise for improvement in nonculture-based diagnostics with new biomarkers of Mucorales DNA that can be used for early diagnosis, and monitoring of response. Antifungal treatment consists of high-dose lipid formulations of amphotericin B or isavuconazole as the first-line therapy and posaconazole as salvage therapy. The new, pharmacokinetically more reliable formulations of posaconazole (intravenous, extended-release tablets) are welcomed improvements. Yet, the role of combination therapy is still uncertain. Surgery had a significant role in selected cases, such as in patients with rhinosinusitis form of mucormycosis, which nowadays can be performed with minimal invasive technique. SUMMARY: Mucormycosis remain a life-threatening opportunistic mold infection among transplant patients. Early diagnosis, prompt treatment with effective antifungals in combination with surgery if feasible is essential. Immune adjunct therapy and improvement of early diagnostics are important areas for future research. There are good prospects of progress in diagnostics and management of mucormycosis in transplant patients.
PURPOSE OF REVIEW: Mucormycosis is an opportunistic mold infection whose management is difficult, as there is a paucity of evidence-based data. We summarize the latest advances in diagnosis and management of mucormycosis in transplant recipients. RECENT FINDINGS: There is promise for improvement in nonculture-based diagnostics with new biomarkers of Mucorales DNA that can be used for early diagnosis, and monitoring of response. Antifungal treatment consists of high-dose lipid formulations of amphotericin B or isavuconazole as the first-line therapy and posaconazole as salvage therapy. The new, pharmacokinetically more reliable formulations of posaconazole (intravenous, extended-release tablets) are welcomed improvements. Yet, the role of combination therapy is still uncertain. Surgery had a significant role in selected cases, such as in patients with rhinosinusitis form of mucormycosis, which nowadays can be performed with minimal invasive technique. SUMMARY:Mucormycosis remain a life-threatening opportunistic mold infection among transplant patients. Early diagnosis, prompt treatment with effective antifungals in combination with surgery if feasible is essential. Immune adjunct therapy and improvement of early diagnostics are important areas for future research. There are good prospects of progress in diagnostics and management of mucormycosis in transplant patients.
Authors: Anuradha Ganesan; Justin Wells; Faraz Shaikh; Philip Peterson; William Bradley; M Leigh Carson; Joseph L Petfield; Mary Klassen-Fischer; Kevin S Akers; Kevin Downing; Ralf Bialek; David R Tribble; Brian L Wickes Journal: J Clin Microbiol Date: 2019-12-23 Impact factor: 5.948
Authors: Jenell Stewart; Gretchen Snoeyenbos Newman; Rupali Jain; Andrew Bryan; Heather Berger; Martin Montenovo; Ramasamy Bakthavatsalam; Catherine E Kling; Lena Sibulesky; Sherene Shalhub; Ajit P Limaye; Cynthia E Fisher; Robert M Rakita Journal: Am J Transplant Date: 2018-10-29 Impact factor: 8.086
Authors: Michael Kueht; Joshua A Villarreal; Edward Reece; N Thao N Galvan; Krupa Mysore; Alejandro Restrepo; Norma Quintanilla; Abbas Rana; John Goss Journal: Plast Reconstr Surg Glob Open Date: 2019-01-15